Tags

Type your tag names separated by a space and hit enter

Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients.
Diabetes Metab. 2009 Sep; 35(4):312-8.DM

Abstract

AIM

This randomised study was designed to investigate the impact of continuous glucose monitoring (CGM) for 48h on glycaemic control with a 3-month follow-up in patients with type 1 (T1D) or type 2 (T2D) diabetes.

METHODS

A total of 48 patients with poor glycaemic control (HbA(1c): 8-10.5%) underwent CGM for 48h using the GlucoDay((R)) system (A. Menarini Diagnostics), after which they were randomly assigned to treatment adjustments based on either their CGM profile (CGM group) or their usual self-monitoring of blood glucose (SMBG group). HbA(1c) measurement and 48-h CGM were repeated 3 months later.

RESULTS

Altogether, 34 patients with either T1D (n=9) or T2D (n=25) completed the study; seven patients chose to leave the study, and seven patients in the CGM group were excluded because their baseline CGM graphs were not interpretable. HbA(1c) levels decreased significantly in the CGM group (n=14, -0.63+/-0.27%; P=0.023), but not in the controls (n=20, -0.28+/-0.21%; P=0.30). In T2D patients, the improvement associated with CGM vs SMBG was due to HbA(1c) decreases (mean: -0.63+/-0.34%; P=0.05 vs -0.31+/-0.29%; P=0.18, respectively). However, HbA(1c) did not change significantly with CGM in T1D patients. Comparisons of CGM data at baseline and after 3 months showed no significant changes in glucose control, glucose variability or hypoglycaemia. No major adverse events related to the GlucoDay system were reported.

CONCLUSION

This is the first randomised study showing that CGM improves glycaemic control in patients with T2D.

Authors+Show Affiliations

Department of Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, AP-HP, Bondy, France. emmanuel.cosson@jvr.aphp.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19560388

Citation

Cosson, E, et al. "Multicentre, Randomised, Controlled Study of the Impact of Continuous Sub-cutaneous Glucose Monitoring (GlucoDay) On Glycaemic Control in Type 1 and Type 2 Diabetes Patients." Diabetes & Metabolism, vol. 35, no. 4, 2009, pp. 312-8.
Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, et al. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes Metab. 2009;35(4):312-8.
Cosson, E., Hamo-Tchatchouang, E., Dufaitre-Patouraux, L., Attali, J. R., Pariès, J., & Schaepelynck-Bélicar, P. (2009). Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes & Metabolism, 35(4), 312-8. https://doi.org/10.1016/j.diabet.2009.02.006
Cosson E, et al. Multicentre, Randomised, Controlled Study of the Impact of Continuous Sub-cutaneous Glucose Monitoring (GlucoDay) On Glycaemic Control in Type 1 and Type 2 Diabetes Patients. Diabetes Metab. 2009;35(4):312-8. PubMed PMID: 19560388.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. AU - Cosson,E, AU - Hamo-Tchatchouang,E, AU - Dufaitre-Patouraux,L, AU - Attali,J-R, AU - Pariès,J, AU - Schaepelynck-Bélicar,P, Y1 - 2009/06/26/ PY - 2008/11/28/received PY - 2009/01/29/revised PY - 2009/02/06/accepted PY - 2009/6/30/entrez PY - 2009/6/30/pubmed PY - 2010/1/9/medline SP - 312 EP - 8 JF - Diabetes & metabolism JO - Diabetes Metab VL - 35 IS - 4 N2 - AIM: This randomised study was designed to investigate the impact of continuous glucose monitoring (CGM) for 48h on glycaemic control with a 3-month follow-up in patients with type 1 (T1D) or type 2 (T2D) diabetes. METHODS: A total of 48 patients with poor glycaemic control (HbA(1c): 8-10.5%) underwent CGM for 48h using the GlucoDay((R)) system (A. Menarini Diagnostics), after which they were randomly assigned to treatment adjustments based on either their CGM profile (CGM group) or their usual self-monitoring of blood glucose (SMBG group). HbA(1c) measurement and 48-h CGM were repeated 3 months later. RESULTS: Altogether, 34 patients with either T1D (n=9) or T2D (n=25) completed the study; seven patients chose to leave the study, and seven patients in the CGM group were excluded because their baseline CGM graphs were not interpretable. HbA(1c) levels decreased significantly in the CGM group (n=14, -0.63+/-0.27%; P=0.023), but not in the controls (n=20, -0.28+/-0.21%; P=0.30). In T2D patients, the improvement associated with CGM vs SMBG was due to HbA(1c) decreases (mean: -0.63+/-0.34%; P=0.05 vs -0.31+/-0.29%; P=0.18, respectively). However, HbA(1c) did not change significantly with CGM in T1D patients. Comparisons of CGM data at baseline and after 3 months showed no significant changes in glucose control, glucose variability or hypoglycaemia. No major adverse events related to the GlucoDay system were reported. CONCLUSION: This is the first randomised study showing that CGM improves glycaemic control in patients with T2D. SN - 1878-1780 UR - https://www.unboundmedicine.com/medline/citation/19560388/Multicentre_randomised_controlled_study_of_the_impact_of_continuous_sub_cutaneous_glucose_monitoring__GlucoDay__on_glycaemic_control_in_type_1_and_type_2_diabetes_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1262-3636(09)00090-1 DB - PRIME DP - Unbound Medicine ER -